The results from two large, prospective, randomized, controlled trials examining the role of 5-α reductase inhibitors in the prevention of prostate cancer have been published. Initial results from the Prostate Cancer Prevention Trial (PCPT) were met with both enthusiasm and skepticism. The recently published REDUCE trial seems to corroborate the findings of the PCPT and reinforce the chemopreventive potential of 5-α reductase inhibitors. This article will assess the REDUCE trial and place the results of the 5-α reductase inhibitor trials in the context of clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366–381 (2003).
Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–249 (2003).
Lucia, M. S. et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev. Res. 1, 167–173 (2008).
Stephenson, A. J., Abouassaly, R. & Klein, E. A. Chemoprevention of prostate cancer. Urol. Clin. N. Am. 37, 11–21 (2010).
Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202 (2010).
Walsh, P. C. Three considerations before advising 5-alpha reductase inhibitors for chemoprevention. J. Clin. Oncol. 27, e22 (2009).
Thompson, I. M. et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl Cancer Inst. 98, 1128–1133 (2006).
Kramer, B. S. et al. Use of 5 alpha reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Urol. 181, 1642–1657 (2009).
Svatek, R. S., Lee, J. J., Roehrborn, C. G., Lippman, S. M. & Lotan, Y. Cost-effectiveness of prostate cancer chemoprevention. Cancer 112, 1058–1065 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E. D. Kim has acted on an advisory board for Eli Lilly and received honoraria from the following companies: Astellas, Sanofi-Aventis and Watson Pharmaceuticals. W. M. White declares no competing interests.
Rights and permissions
About this article
Cite this article
White, W., Kim, E. Evolving role of 5-α reductase inhibitors in chemoprevention. Nat Rev Clin Oncol 7, 487–488 (2010). https://doi.org/10.1038/nrclinonc.2010.114
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.114
